

Haematologica  
HAEMATOL/2019/230276  
Version 4

Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies

Thomas Pincez, Julie Bruneau, Laureline Berteloot, Eve Piekarski, Caroline Thomas, Ambroise Marçais, Amélie Trinquand, Martin Castelle, Nicolas Garcelon, Dominique Plantaz, Morgane Cheminant, Despina Moshous, Thierry Jo Molina, Olivier Hermine, Elizabeth Macintyre, Alain Fischer, Stéphane Blanche, Felipe Suarez, and Bénédicte Neven

Disclosures: None

Contributions: TP, AF, FS and BN designed the study. TP gathered clinical data. JB and TJM reviewed pathology. LB reviewed CT scan. EP reviewed PET-CT. AT performed clonality analysis. AT and EM analyzed the clonality results. NG identified the patients to include. CT, AM, DP, MC, DM, SB, OH, AF, FS and BN were in charge of the patients. TP, FS and BN wrote the manuscript. All authors critically read the manuscript, approved final version, and agreed to be accountable for all aspects of the work.